These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8336496)

  • 21. Urinalysis for the private office laboratory.
    Voldish K
    N J Med; 1991 Nov; 88(11):819-20. PubMed ID: 1758650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of drug abuse by health professionals.
    Meeker JE; Mount AM; Ross W
    Occup Health Saf; 2002 Aug; 71(8):46-50. PubMed ID: 12197441
    [No Abstract]   [Full Text] [Related]  

  • 23. [Adulteration of urine drug testing--an exaggerated cause of concern].
    Beck O; Bohlin M; Bragd F; Bragd J; Greitz O
    Lakartidningen; 2000 Feb; 97(7):703-6. PubMed ID: 10740378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Uniform analyzes of drugs in urine needed for rule of law].
    Hansson T; Helander A; Beck O; Elmgren A; Kugelberg F; Kronstrand R
    Lakartidningen; 2015 Sep; 112():. PubMed ID: 26393972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. European guidelines for workplace drug testing in urine.
    Taskinen S; Beck O; Bosch T; Brcak M; Carmichael D; Fucci N; George C; Piper M; Salomone A; Schielen W; Steinmeyer S; Weinmann W
    Drug Test Anal; 2017 Jun; 9(6):853-865. PubMed ID: 28267298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quality control in urinalysis.
    Takubo T; Tatsumi N
    Southeast Asian J Trop Med Public Health; 1999; 30 Suppl 3():136-48. PubMed ID: 10926274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of World Anti-Doping Agency criteria for anabolic agent analysis by using comprehensive two-dimensional gas chromatography-mass spectrometry.
    Mitrevski BS; Wilairat P; Marriott PJ
    Anal Bioanal Chem; 2010 Apr; 396(7):2503-11. PubMed ID: 20091298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Finnish guidelines for workplace drug testing.
    Lillsunde P; Haavanlammi K; Partinen R; Mukala K; Lamberg M
    Forensic Sci Int; 2008 Jan; 174(2-3):99-102. PubMed ID: 17499950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Catching Fakes: New Markers of Urine Sample Validity and Invalidity.
    Goggin MM; Tann CM; Miller A; Nguyen A; Janis GC
    J Anal Toxicol; 2017 Mar; 41(2):121-126. PubMed ID: 27881620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multiple-site laboratory evaluation of three on-site urinalysis drug-testing devices.
    Crouch DJ; Frank JF; Farrell LJ; Karsch HM; Klaunig JE
    J Anal Toxicol; 1998 Oct; 22(6):493-502. PubMed ID: 9788525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Choosing the right laboratory: a review of clinical and forensic toxicology services for urine drug testing in pain management.
    Reisfield GM; Goldberger BA; Bertholf RL
    J Opioid Manag; 2015; 11(1):37-44. PubMed ID: 25750163
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ASVCP quality assurance guidelines: control of preanalytical, analytical, and postanalytical factors for urinalysis, cytology, and clinical chemistry in veterinary laboratories.
    Gunn-Christie RG; Flatland B; Friedrichs KR; Szladovits B; Harr KE; Ruotsalo K; Knoll JS; Wamsley HL; Freeman KP;
    Vet Clin Pathol; 2012 Mar; 41(1):18-26. PubMed ID: 22390424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative evaluation of the accuracy of benzodiazepine testing in chronic pain patients utilizing immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing.
    Manchikanti L; Malla Y; Wargo BW; Fellows B
    Pain Physician; 2011; 14(3):259-70. PubMed ID: 21587329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Present and future opportunities.
    Kenney JE
    Occup Health Saf; 2005 Aug; 74(8):84, 86. PubMed ID: 16212029
    [No Abstract]   [Full Text] [Related]  

  • 35. [Identification of drug abuse].
    Skender L
    Arh Hig Rada Toksikol; 1997 Dec; 48(4):403-11. PubMed ID: 9721459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selection of an appropriate initial test cutoff concentration for workplace drug urinalysis--Cannabis example.
    Liu RH; Edwards C; Baugh LD; Weng JL; Fyfe MJ; Walia AS
    J Anal Toxicol; 1994; 18(2):65-70. PubMed ID: 8207936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recommendations for urine drug monitoring as a component of opioid therapy in the treatment of chronic pain.
    Peppin JF; Passik SD; Couto JE; Fine PG; Christo PJ; Argoff C; Aronoff GM; Bennett D; Cheatle MD; Slevin KA; Goldfarb NI
    Pain Med; 2012 Jul; 13(7):886-96. PubMed ID: 22694154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adulterants in Urine Drug Testing.
    Fu S
    Adv Clin Chem; 2016; 76():123-63. PubMed ID: 27645818
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug screening in the workplace: ethical guidelines.
    J Occup Med; 1991 May; 33(5):651-2. PubMed ID: 1870021
    [No Abstract]   [Full Text] [Related]  

  • 40. [Analyses of narcotics in urine--valuable if correctly done and competently used].
    Edhag O
    Lakartidningen; 1991 Oct; 88(40):3261. PubMed ID: 1943333
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.